Another one for Boston Scientific to put down to experience
This article was originally published in Clinica
Executive Summary
News last week that the US Food & Drug Administration had lifted the remaining restrictions on Boston Scientific's implantable cardiac defibrillators (ICD) and cardiac resynchronisation therapy (CRT) devices was welcomed at a company that has not had the rub of the green this year.